Pay in 4 interest-free payments of $5.76 Learn more
Ships within 48 hours · Estimated delivery Aug 12 - Aug 17
The key difference is that Retatrutide is designed as a triple agonist, with activity at GLP-1, GIP, and glucagon receptors
:max_bytes(150000):strip_icc()/health-GettyImages-2025836701-ce3f5ccf0f98428e9d14abaeb07ba307.jpg)
Generally in the U.S., healthcare technologies and services are considered cost-effective if theyre below $150,000 per QALY
In Tirzepatide GIP increases energy expenditure , resulting in weight loss reductions
GLP-1 Market Share, By Drug Class, 2025 (%) The triple agonists (Pipeline) segment held a 3% share of the market in 2025 and is expected to grow at the fastest CAGR of 29.4% during the projection period
US$ 27.48
US$ 26.16
US$ 25.09
US$ 27.58
US$ 28.99
US$ 29.40
US$ 24.32
US$ 29.34
US$ 22.44
US$ 21.82
.webp)
US$ 23.23
US$ 20.60
US$ 28.19
